DiabetesNCT06620094
The EFFECT of MOBILE APPLICATION USE on DIABETES CONTROL in DIABETIC PATIENTS
A study testing diabetes education videos in people with Diabetes, run by Inonu University at 1 site in Turkey (Türkiye).
Trial summary
Objective:This study aims to determine the effect of a mobile application on diabetes control in patients with Type 2 diabetes. Methods:This study is a randomized controlled trial with a pre-test and post-test design. Read more about this study
- Who is it for?
- Ages 35 to 65 years
- Conditions the study is for
- Diabetes
- What is being tested?
- diabetes education videos
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 30 May 2021to 30 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Having been diagnosed with type 2 diabetes mellitus for at least 6 months. Being between the ages of 40-65. Receiving oral antidiabetic treatment. Having an A1C value between 7%-10%. Owning a mobile phone capable of receiving and playing video messages. Not having sensory impairments, such as hearing or speech loss, or psychiatric problems that prevent communication.
Who cannot join
- Inability to use the mobile application. Patients with a psychological diagnosis according to records. Patients using insulin. Having an A1C value above 10%. Having an infection requiring medication.
Trial locations and contacts
1 site in 1 country.
About this study
Objective:This study aims to determine the effect of a mobile application on diabetes control in patients with Type 2 diabetes.
Methods:This study is a randomized controlled trial with a pre-test and post-test design. The study population consists of Type 2 diabetes patients who applied to the Endocrinology Clinic of Malatya Turgut Özal Medical Center. A total of 70 participants were included in the study. Data were collected face-to-face using a demographic data collection form, a diabetes diagnosis and follow-up form, and the Turkish Multidimensional Diabetes Scale. The data were analyzed using paired t-tests and independent samples t-tests to compare means, counts, and percentages in dependent and independent groups.
Read the detailed description
Type of Study: This study is a pre-test, post-test randomized controlled experimental study.
Population and Sample of the Study: The population of the study consisted of individuals with type 2 diabetes who applied to the Endocrinology Clinic of Malatya Inonu University Turgut Ozal Medical Center between May 2021 and December 2021. The sample included patients who met the inclusion criteria during the dates of the study and who applied to the Endocrinology Clinic. The power analysis used to determine the sample size was calculated with a 5% margin of error, 95% confidence interval at a two-sided significance level, and 80% population representation capacity, with 50 diabetic individuals for each group (50 experimental, 50 control). However, the study was completed with 38 individuals in the experimental group and 32 in the control group.
Inclusion Criteria:
Having been diagnosed with type 2 diabetes mellitus for at least 6 months. Being between the ages of 40-65. Receiving oral antidiabetic treatment. Having an A1C value between 7%-10%. Owning a mobile phone capable of receiving and playing video messages. Not having sensory impairments, such as hearing or speech loss, or psychiatric problems that prevent communication.
Exclusion Criteria:
Inability to use the mobile application. Patients with a psychological diagnosis according to records. Patients using insulin. Having an A1C value above 10%. Having an infection requiring medication. Randomization: Care was taken to ensure that the two groups were homogeneous by considering all variables. The assignment of diabetic patients to the experimental and control groups was done through randomization to avoid bias. The randomization was carried out using the Random Integer Generator method in the Numbers section of the random.org website, where columns with five groups between 1-100 were generated. Patients who applied to the Endocrinology Clinic were randomized to numbers 1 and 2, based on which they were assigned to the groups. The determination of which number corresponded to the experimental or control group was made by drawing lots at the beginning of the study.
Data Collection Tools: Two data collection tools were used to collect the data.
Diabetes Patient Identification and Monitoring Form: This form, prepared by the researchers with the help of literature reviews and expert opinions, consists of three parts. The first part contains 11 items used to determine the socio-demographic characteristics of the patient. The second part consists of 32 items that question the patient's diabetes-related characteristics, such as diabetes type, treatment method, complications, treatment follow-up routines, nutrition, exercise routines, foot care, diabetes-related knowledge, and habits. The third part consists of 9 items that question the metabolic control characteristics of diabetic individuals, such as fasting blood sugar, A1C, total cholesterol, LDL, HDL, triglycerides, blood pressure, height, weight, and body mass index.
Turkish Multidimensional Diabetes Questionnaire (T-MDQ): This scale was developed by Talbot and colleagues in 1997. The Turkish validity and reliability of the scale were conducted by Coşansu and Erdoğan in 2010. The scale consists of 40 items, 7 sub-dimensions, and 3 sections. The scale has no total score, and each sub-dimension is evaluated separately.
Section: Focuses on the general perception of diabetes and social support. This section consists of three sub-dimensions and 16 items. The Perceived Barrier sub-dimension consists of 9 items questioning how much the patient\'s daily activities such as work, social, and leisure activities are negatively affected and limited due to diabetes. The Perceived Severity consists of 3 items measuring the degree of the patient\'s perception of the seriousness of diabetes. The Perceived Social Support sub-dimension consists of 4 items questioning the patient\'s perceived social support from important people in their life, such as family, friends, and healthcare professionals. In the first section, responses are obtained with a 7-point Likert scale (0-none, 6-very much). The scores of the items answered by the individual for each sub-dimension are summed and divided by the number of items answered to obtain an average score. Higher scores indicate higher perceived barriers, social support, and severity levels.
Section: Investigates the behaviors of the patient's spouse or someone significant to them that either support or fail to support the patient's self-care activities for diabetes. This section consists of two sub-dimensions and 12 items. Positive Supportive Behaviors consist of 8 items aimed at identifying positive behaviors of the patient\'s spouse or significant other that support the patient\'s management of diabetes. The Misleading Supportive Behaviors sub-dimension consists of 4 items aimed at identifying supportive but bothersome and unhelpful behaviors of the patient\'s spouse or significant other. Responses in the second section are recorded on a 7-point Likert scale (0-never, 6-always). Individuals living alone do not fill out this section.
Section: Measures the individual\'s perception of self-efficacy and outcome expectations related to disease management. This section consists of two sub-dimensions and 13 items. The Perceived Self-Efficacy sub-dimension consists of 7 items that determine the individual's confidence in performing self-care activities for their illness. Responses are recorded on a Likert scale (0-not confident at all, 100-very confident). The Perceived Outcome Expectation sub-dimension consists of 6 items that evaluate the individual\'s perception of the effectiveness of self-care behaviors and treatment in achieving metabolic control and preventing complications. Responses are recorded on a Likert scale (0-not important at all, 100-very important). Higher scores indicate higher perceived self-efficacy and outcome expectations.
Data Collection: The data of the study were collected through face-to-face interviews by the researcher with type 2 diabetic patients who applied to the Endocrinology Clinic between May 2021 and December 2021. Patients meeting the inclusion criteria were included in the study.
Initially, data collection forms (survey form and T-MDQ) were applied to the patients in the experimental and control groups. Additionally, patients\' test results (A1C, glucose, total cholesterol, HDL, LDL, triglycerides), blood pressure, height, and weight measurements were recorded during routine outpatient follow-ups. The experimental group received education and follow-up for three months through a mobile application prepared for diabetic patients. At the end of this period, the T-MDQ, routine test results (A1C, glucose, total cholesterol, HDL, LDL, triglycerides), blood pressure, height, and weight measurements were applied again to both the experimental and control groups.
Intervention: During the initial interview with the experimental group, participants were informed about notifications and diabetes education videos that would be sent to their phones. Following this, notifications were sent three times a day, every day of the week. The first notification asked the patient to ;measure and record their fasting and postprandial blood sugar in the morning,\" the second instructed to \"exercise for at least 30 minutes a day,\" and the third asked them to \"record the foods and amounts they ate, measure and record their evening fasting and postprandial blood sugar, and measure and record their blood sugar before going to bed.\" The results of their routine outpatient tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides), blood pressure, and weight measurements were recorded. In addition, three times a week, participants were asked to \"measure and record their blood pressure and weight, and log the recorded information in the app each time; During the three-month period, individuals continued their routine outpatient follow-ups.
Control Group: During the first meeting, after being informed about the study, data collection forms (survey form and Turkish Multidimensional Diabetes Questionnaire) were applied to the control group. The results of the routine outpatient tests (A1C, glucose, total cholesterol, HDL, LDL, triglycerides) were recorded. Blood pressure, height, and weight measurements were taken, and the first interview was completed. The control group continued their routine outpatient follow-ups. During the second meeting, which took place three months later, the data collection forms were applied again. The results of routine outpatient tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides) were written down, and blood pressure and weight measurements were taken and recorded.
- Conditions
- Diabetes
- Being tested
- diabetes education videos
- Keywords
- Diabetes mellitus, glycated hemoglobin A, mobile applications
- Medical subject headings
- Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
diabetes education videosOther
In the initial meeting during the preparation phase, participants in the experimental group were informed about the notifications and diabetes education videos that would be sent to their phones. Afterward, the patients received three notifications daily, every day of the week. The first notification requested them to ;measure and record their fasting and postprandial blood sugar in the morning; The second notification instructed them to ;exercise for at least 30 minutes a day.; The third notification asked them to ;record the foods they consumed and their quantities, and to measure and record their evening fasting and postprandial blood sugar, as well as their blood sugar before going to bed.; Additionally, during their routine outpatient follow-ups, the results of their tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides), blood pressure, and weight measurements were recorded. Furthermore, three times a week, participants were asked to ;measure and record their blood pressur
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Experimental | This group, used mobile application and underwent routine controls. Receives: Other: diabetes education videos |
| Control Group | No intervention | This group, underwent only routine controls. |
What is being measured
The primary outcome is the main question the study is designed to answer.
A1C levels
Hemoglobin A1C (HbA1C): HbA1C is a blood test that measures the average blood glucose levels over the past two to three months by determining the percentage of glycated hemoglobin in the blood. It is commonly used to diagnose diabetes and assess the effectiveness of diabetes management. An HbA1C level below 5.7% is considered normal, between 5.7% and 6.4% indicates prediabetes, and a level of 6.5% or higher indicates diabetes.
Measured: up to seven months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start30 May 2021
- Primary completion30 Dec 2021
- Study completion30 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- More trials run by Inonu UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a pre-test, post-test randomized controlled experimental study. Therefore this study there is two groups: Intervention and control.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 38 participants (actual)
Sponsor and investigators
- Lead sponsor
- Inonu University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fidan Balkaya, Inonu University
- Investigators
- Rukuye AYLAZ, Prof. Dr., Study director, Inonu University Faculty of Nursing
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06620094
- Sponsor's protocol ID
- Faculty of Nursing
- Other IDs
- TSA-2021-2582
- Status last verified
- Sep 2024
- First submitted
- 24 Sep 2024
- Last updated
- 1 Oct 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data are not open to public due to confidentiality and ethical restrictions.
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The EFFECT of MOBILE APPLICATION USE on DIABETES CONTROL in DIABETIC PATIENTS
- ClinicalTrials.gov ID
- NCT06620094
- Acronym / sponsor ID
- Faculty of Nursing
- Conditions
- Diabetes
- Keywords
- Diabetes mellitus, glycated hemoglobin A, mobile applications
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 38 participants (actual)
- Lead sponsor
- Inonu UniversityUniversity, hospital or other
- Study start
- 30 May 2021 (actual)
- Primary completion
- 30 Dec 2021 (actual)
- Study completion
- 30 Dec 2021 (actual)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective:This study aims to determine the effect of a mobile application on diabetes control in patients with Type 2 diabetes.
Methods:This study is a randomized controlled trial with a pre-test and post-test design. The study population consists of Type 2 diabetes patients who applied to the Endocrinology Clinic of Malatya Turgut Özal Medical Center. A total of 70 participants were included in the study. Data were collected face-to-face using a demographic data collection form, a diabetes diagnosis and follow-up form, and the Turkish Multidimensional Diabetes Scale. The data were analyzed using paired t-tests and independent samples t-tests to compare means, counts, and percentages in dependent and independent groups.
Detailed description
Type of Study: This study is a pre-test, post-test randomized controlled experimental study.
Population and Sample of the Study: The population of the study consisted of individuals with type 2 diabetes who applied to the Endocrinology Clinic of Malatya Inonu University Turgut Ozal Medical Center between May 2021 and December 2021. The sample included patients who met the inclusion criteria during the dates of the study and who applied to the Endocrinology Clinic. The power analysis used to determine the sample size was calculated with a 5% margin of error, 95% confidence interval at a two-sided significance level, and 80% population representation capacity, with 50 diabetic individuals for each group (50 experimental, 50 control). However, the study was completed with 38 individuals in the experimental group and 32 in the control group.
Inclusion Criteria:
Having been diagnosed with type 2 diabetes mellitus for at least 6 months. Being between the ages of 40-65. Receiving oral antidiabetic treatment. Having an A1C value between 7%-10%. Owning a mobile phone capable of receiving and playing video messages. Not having sensory impairments, such as hearing or speech loss, or psychiatric problems that prevent communication.
Exclusion Criteria:
Inability to use the mobile application. Patients with a psychological diagnosis according to records. Patients using insulin. Having an A1C value above 10%. Having an infection requiring medication. Randomization: Care was taken to ensure that the two groups were homogeneous by considering all variables. The assignment of diabetic patients to the experimental and control groups was done through randomization to avoid bias. The randomization was carried out using the Random Integer Generator method in the Numbers section of the random.org website, where columns with five groups between 1-100 were generated. Patients who applied to the Endocrinology Clinic were randomized to numbers 1 and 2, based on which they were assigned to the groups. The determination of which number corresponded to the experimental or control group was made by drawing lots at the beginning of the study.
Data Collection Tools: Two data collection tools were used to collect the data.
Diabetes Patient Identification and Monitoring Form: This form, prepared by the researchers with the help of literature reviews and expert opinions, consists of three parts. The first part contains 11 items used to determine the socio-demographic characteristics of the patient. The second part consists of 32 items that question the patient's diabetes-related characteristics, such as diabetes type, treatment method, complications, treatment follow-up routines, nutrition, exercise routines, foot care, diabetes-related knowledge, and habits. The third part consists of 9 items that question the metabolic control characteristics of diabetic individuals, such as fasting blood sugar, A1C, total cholesterol, LDL, HDL, triglycerides, blood pressure, height, weight, and body mass index.
Turkish Multidimensional Diabetes Questionnaire (T-MDQ): This scale was developed by Talbot and colleagues in 1997. The Turkish validity and reliability of the scale were conducted by Coşansu and Erdoğan in 2010. The scale consists of 40 items, 7 sub-dimensions, and 3 sections. The scale has no total score, and each sub-dimension is evaluated separately.
Section: Focuses on the general perception of diabetes and social support. This section consists of three sub-dimensions and 16 items. The Perceived Barrier sub-dimension consists of 9 items questioning how much the patient\'s daily activities such as work, social, and leisure activities are negatively affected and limited due to diabetes. The Perceived Severity consists of 3 items measuring the degree of the patient\'s perception of the seriousness of diabetes. The Perceived Social Support sub-dimension consists of 4 items questioning the patient\'s perceived social support from important people in their life, such as family, friends, and healthcare professionals. In the first section, responses are obtained with a 7-point Likert scale (0-none, 6-very much). The scores of the items answered by the individual for each sub-dimension are summed and divided by the number of items answered to obtain an average score. Higher scores indicate higher perceived barriers, social support, and severity levels.
Section: Investigates the behaviors of the patient's spouse or someone significant to them that either support or fail to support the patient's self-care activities for diabetes. This section consists of two sub-dimensions and 12 items. Positive Supportive Behaviors consist of 8 items aimed at identifying positive behaviors of the patient\'s spouse or significant other that support the patient\'s management of diabetes. The Misleading Supportive Behaviors sub-dimension consists of 4 items aimed at identifying supportive but bothersome and unhelpful behaviors of the patient\'s spouse or significant other. Responses in the second section are recorded on a 7-point Likert scale (0-never, 6-always). Individuals living alone do not fill out this section.
Section: Measures the individual\'s perception of self-efficacy and outcome expectations related to disease management. This section consists of two sub-dimensions and 13 items. The Perceived Self-Efficacy sub-dimension consists of 7 items that determine the individual's confidence in performing self-care activities for their illness. Responses are recorded on a Likert scale (0-not confident at all, 100-very confident). The Perceived Outcome Expectation sub-dimension consists of 6 items that evaluate the individual\'s perception of the effectiveness of self-care behaviors and treatment in achieving metabolic control and preventing complications. Responses are recorded on a Likert scale (0-not important at all, 100-very important). Higher scores indicate higher perceived self-efficacy and outcome expectations.
Data Collection: The data of the study were collected through face-to-face interviews by the researcher with type 2 diabetic patients who applied to the Endocrinology Clinic between May 2021 and December 2021. Patients meeting the inclusion criteria were included in the study.
Initially, data collection forms (survey form and T-MDQ) were applied to the patients in the experimental and control groups. Additionally, patients\' test results (A1C, glucose, total cholesterol, HDL, LDL, triglycerides), blood pressure, height, and weight measurements were recorded during routine outpatient follow-ups. The experimental group received education and follow-up for three months through a mobile application prepared for diabetic patients. At the end of this period, the T-MDQ, routine test results (A1C, glucose, total cholesterol, HDL, LDL, triglycerides), blood pressure, height, and weight measurements were applied again to both the experimental and control groups.
Intervention: During the initial interview with the experimental group, participants were informed about notifications and diabetes education videos that would be sent to their phones. Following this, notifications were sent three times a day, every day of the week. The first notification asked the patient to ;measure and record their fasting and postprandial blood sugar in the morning,\" the second instructed to \"exercise for at least 30 minutes a day,\" and the third asked them to \"record the foods and amounts they ate, measure and record their evening fasting and postprandial blood sugar, and measure and record their blood sugar before going to bed.\" The results of their routine outpatient tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides), blood pressure, and weight measurements were recorded. In addition, three times a week, participants were asked to \"measure and record their blood pressure and weight, and log the recorded information in the app each time; During the three-month period, individuals continued their routine outpatient follow-ups.
Control Group: During the first meeting, after being informed about the study, data collection forms (survey form and Turkish Multidimensional Diabetes Questionnaire) were applied to the control group. The results of the routine outpatient tests (A1C, glucose, total cholesterol, HDL, LDL, triglycerides) were recorded. Blood pressure, height, and weight measurements were taken, and the first interview was completed. The control group continued their routine outpatient follow-ups. During the second meeting, which took place three months later, the data collection forms were applied again. The results of routine outpatient tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides) were written down, and blood pressure and weight measurements were taken and recorded.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- This study is a pre-test, post-test randomized controlled experimental study. Therefore this study there is two groups: Intervention and control.
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Experimental | Other: diabetes education videosThis group, used mobile application and underwent routine controls. |
| Control Group | No intervention | –This group, underwent only routine controls. |
Who may qualify
- Ages
- 35 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Having been diagnosed with type 2 diabetes mellitus for at least 6 months. Being between the ages of 40-65. Receiving oral antidiabetic treatment. Having an A1C value between 7%-10%. Owning a mobile phone capable of receiving and playing video messages. Not having sensory impairments, such as hearing or speech loss, or psychiatric problems that prevent communication.
Key exclusion criteria (1 listed)
- Inability to use the mobile application. Patients with a psychological diagnosis according to records. Patients using insulin. Having an A1C value above 10%. Having an infection requiring medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| diabetes education videosIn the initial meeting during the preparation phase, participants in the experimental group were informed about the notifications and diabetes education videos that would be sent to their phones. Afterward, the patients received three notifications daily, every day of the week. The first notification requested them to ;measure and record their fasting and postprandial blood sugar in the morning; The second notification instructed them to ;exercise for at least 30 minutes a day.; The third notification asked them to ;record the foods they consumed and their quantities, and to measure and record their evening fasting and postprandial blood sugar, as well as their blood sugar before going to bed.; Additionally, during their routine outpatient follow-ups, the results of their tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides), blood pressure, and weight measurements were recorded. Furthermore, three times a week, participants were asked to ;measure and record their blood pressur | Other | Intervention Group |
Primary outcome
A1C levels
Time frame: up to seven months
Hemoglobin A1C (HbA1C): HbA1C is a blood test that measures the average blood glucose levels over the past two to three months by determining the percentage of glycated hemoglobin in the blood. It is commonly used to diagnose diabetes and assess the effectiveness of diabetes management. An HbA1C level below 5.7% is considered normal, between 5.7% and 6.4% indicates prediabetes, and a level of 6.5% or higher indicates diabetes.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2024.
- Individual participant dataSharing planned: No. The data are not open to public due to confidentiality and ethical restrictions.
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rukuye AYLAZ, Prof. Dr. study director
Inonu University Faculty of Nursing
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing diabetes education videos in people with Diabetes, run by Inonu University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
A1C levels (time frame: up to seven months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2024.